SHARE

France, Innovation, 2017

Telomium continues to develop their product

15th July 2019

Telomium, one of the winners of the French Innovation Journey from Education to Business

After applying the vaccine to three monkeys without secondary reactions, Telomium continues to develop their immunotherapy product against cancer.

Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy. Their first-in-class ribonucleoprotein vaccine has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology using a breakthrough innovation in the production of recombinant telomerase.

After defining the best use of their product, Telomium plans to raise founds in order so start their regular preclinical development then performing clinical trials in humans and setting a deal with a big pharma group

New Industry-led Pact for Skills Partnership for the European Health and Life Sciences Sector Launched

New Industry-led Pact for Skills Partnership for the European Health and Life Sciences Sector Launched

Read more about the partnership

Find out more

Paediatric Health Innovator Named Winners At Wild Card 2023 Awards Ceremony

Paediatric Health Innovator Named Winners At Wild Card 2023 Awards Ceremony

Find out who won

Find out more

EIT Health Awards 12 Elder Care Start-ups up to €50K

EIT Health Awards 12 Elder Care Start-ups up to €50K

Discover the awardees

Find out more